
Opinion|Videos|November 11, 2024
JAK Inhibition in the Treatment of Alopecia Areata
Key Takeaways
- Baricitinib and deuruxolitinib inhibit JAK1/2, while ritlecitinib targets JAK3 and TEC, reflecting different mechanisms of action in alopecia treatment.
- Selective inhibition focuses on specific JAK pathways, potentially minimizing off-target effects and improving safety profiles.
Panelists discuss the differences in mechanisms of action among the FDA-approved Janus kinase (JAK) inhibitors for alopecia, including baricitinib, deuruxolitinib, and ritlecitinib, and explore how selective inhibition differs from pan-inhibition in influencing treatment efficacy.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Three JAK inhibitors are FDA-approved for the treatment of alopecia: baricitinib and deuruxolitinib (JAK1/2 inhibitors), and ritlecitinib (selective JAK3 and TEC inhibitor). Can you talk about the differences in mechanisms of action and how they might influence treatment efficacy for alopecia?
How does selective inhibition differ from pan-inhibition?
Advertisement
Related to this article

Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.
Advertisement
Advertisement
Trending on HCPLive
1
Single Annual Injection Produces Significant and Sustained Lp(a) Reductions
2
Ruvonoflast Reduces hsCRP, Inflammation, CVD Risk With Downstream Effects
3
One COPD Exacerbation Is Too Many: Vickram Tejwani, MD
4
RAPID: Etripamil Converts Two-Thirds of Recurrent PSVT Episodes After Ablation
5




